Laboratory Pragya Research Laboratories Pvt. Ltd., H-165, Second Floor, Sector-

63, Noida, Uttar Pradesh

Accreditation Standard ISO/IEC 17025: 2005

Certificate Number TC-7873 Page 1 of 6

Validity 26.09.2018 to 25.09.2020 Last Amended on --

SI.		Specific Test Performed	Test Method Specification		7
	i of Test	 	against which tests are performed	Limits of Detection	ļ

BIOLOGICAL TESTING

I	DRUGS AND PHARMACEUTICALS			
A .	Antibiotics		T	
1.	Tablets	Erythromycin Estolate	USP 41 (81)	70% to 150%
1	 	Erythromycin Stearate	IP 2018,Vol. I	70% to 150%
į		į	2.2.10	į į
<u> </u>	<u> </u>	 	(cup-plate method)	
2.	Injection	Amikacin Sulphate	IP 2018,Vol. I	70% to 150%
1	 		2.2.10	
i		<u> </u>	(cup-plate method)	
į		Gentamicin Sulphate	IP 2018,Vol. I	70% to 150%
}		1	(cup-plate method)	
Ì		Streptomycin Sulphate	IP 2018,Vol. I	70% to 150%
Ì	 	Streptornycin Sulphate	2.2.10	70% 10 150%
İ			cup-plate method)	
B.	Endotoxins		t (cup-plate method)	
1.	Parenteral	Bacterial endotoxin Test	IP 2018,Vol. I	Pass /Fail
	Preparations	(Gel Clot Method)	2.2.3	1 465 /1 4
ļ	Injection	(į į
ł	small and Large		USP 41(85)	
-	volume			
į	parenteral)	į	į	į į
2	Surgical Devices,	·	T	
į	Transfusion,	į	į	į į
1	Infusion, Blood			
	Bags and			
İ	disposable,	İ	İ	i i
}	Blades, Syringes			
į	and needles	ļ	ļ	į
L	L	.L	L	.L

Suman Kharayat Convenor

Accreditation Standard ISO/IEC 17025: 2005

Page 2 of 6 **Certificate Number** TC-7873

26.09.2018 to 25.09.2020 Validity Last Amended on --

SI.	Product / Material of Test	Specific Test Performed	Test Method Specification against which tests are performed	Range of Testing / Limits of Detection
C.	Drug Substances (Active Pharmaceuticals Ingredients)		 	
1.	Solid Oral Dosages (Tablet and Capsules)	Total Aerobic Microbial count / Total Aerobic viable count	IP 2018 Vol. I 2.2.9 USP 41 (61)	≥10cfu/g
 	, , 	Total Fungal Count/Yeast and mould Count	IP 2018, Vol. I 2.2.9 USP 41 (61)	≥10cfu/g
 		Escherichia Coli	IP 2018, Vol. I 2.2.9 USP 41 (62)	Present / Absent per g or10g
 	 	Salmonella	IP 2018, Vol. 2.2.9 USP 41 (62)	Present / Absent per g or 10g
 		Staphylococcus aureus	IP 2018, Vol. I 2.2.9 USP 41 (62)	Present / Absent per g or 10g
 	 	Shigella	IP 2018 ,Vol. I 2.2.9	Present / Absent per g or 10g
 		Pseudomonas aeruginosa	IP 2018, Vol. I 2.2.9 USP 41 (62)	Present / Absent per g or 10g
 		Candida albicans	IP 2018, Vol. I 2.2.9 USP 41 (62)	Present / Absent per g or 10g
 		Clostridia	IP 2018, Vol. I 2.2.9 USP 41 (62)	Present / Absent per g
 		Bile-Tolerant Gram- Negative Bacteria	IP 2018, Vol. I 2.2.9, USP 41 (62)	Present / Absent per g or 10g
2.	Liquid Oral Dosages (Syrup)	Total Aerobic Microbial count/ Total Aerobic viable count	IP 2018 2.2.9 USP 41 (61)	≥10 cfu/ml

Accreditation Standard ISO/IEC 17025: 2005

Page 3 of 6 **Certificate Number** TC-7873

26.09.2018 to 25.09.2020 Validity Last Amended on --

SI.	Product / Material of Test	Specific Test Performed	Test Method Specification against which tests are performed	Range of Testing / Limits of Detection
	 	Yeast and mould Count /Yeast and mould Count	IP 2018 2.2.9 USP 41 (61)	≥10 cfu/ml
	 	Escherichia Coli	IP 2018 2.2.9 USP 41 (62)	Present / Absent per g/ml or10g/ml
	 	Salmonella	IP 2018 2.2.9, USP 41 (62)	Present/Absent per g/ml or 10g/ml
	 	Staphylococcus aureus	IP 2018 2.2.9 USP 41 (62)	Present/Absent per g/ml or 10g/ml
	 	Shigella	IP 2018 2.2.9,	Present/Absent per g/ml or 10g/ml
		Pseudomonas aeruginosa	IP 2018 2.2.9, USP 41 (62)	Present/Absent per g/ml or 10g/ml
	 	Candida albicans	IP 2018 2.2.9, USP 41 (62)	Present/Absent per g/ml or 10g/ml
		Clostridia	IP 2014 Page No. 46 USP 41 (61& 62)	Present/Absent per g/ml or 10g/ml
	1 	Bile-Tolerant Gram- Negative Bacteria	IP 2018 2.2.9 USP 41 (62)	Present/Absent per g/ml or 10g/ml

Accreditation Standard ISO/IEC 17025: 2005

Page 4 of 6 **Certificate Number** TC-7873

26.09.2018 to 25.09.2020 **Validity** Last Amended on --

SI.	Product / Material	Specific Test Performed	Test Method Specification	Range of Testing /
į	of Test		against which tests are	Limits of Detection
L	 	 	performed	<u> </u>

CHEMICAL TESTING

T.	DRUGS& PHARMA	CEUTICALS	 !	
A .	Raw material	Ţ	<u> </u>	
	General Test	Identification By IR	IP 2018 Page No.178 - 183	Qualitative
	1	Specific Optical rotation/	IP 2018 Page No.212 - 214	±0 to 360°
į		optical Rotation	<u>i </u>	<u> </u>
 	 	Heavy metals	IP 2018 Page No.139 - 140	Qualitative
 	 	Loss on Drying	IP 2018 Page No.208 -209	0.1% to 20% w/w
l I		Melting Point	IP 2018 Page No.209 - 212	Qualitative
	 	pH	IP 2018 Page No.215 - 216	1 to 14
	 	Water by KF	IP 2018 Page No.156	0.1 to 15%w/w
 	 	Sulphates	IP 2018 Page No.140	Qualitative
_B.	Tablets and Capsul		 	
1.	General Test	Disintegration	IP 2018 Page No.299 - 302	1 minute to 180 minutes
		Dissolution	IP 2018	50 % to 150 %
į	 -	<u></u>	Page No.302 to 308	of label claim
 	 	Uniformity of weight	IP 2018	0.06 g to 5.0 g
	 		Page No. 1085	ļ
		L	Page No. 308	
İ		Uniformity of content	IP 2018	80 % to 150 %
 - <u>-</u>	 -	 	Page No. 308 to 309	of average value
2.	Acelofenac Tablet	Identification	IP 2018 Page No.1145	Qualitative
 	(IP)	(By HPLC)	 	70 to 420 %
į		Assay	IP 2018 Page No.1145- 1146	70 to 120 %
l I	[]	(By HPLC) Dissolution		of label claim 50 to 120%
į		(By UV)	IP 2018 Page No.1145	of label claim
3.	Atorvastatin	Identification	IP 2018 Page No.1287-	Qualitative
J.	Tablet IP	(By HPLC)	1289	Qualitative
	ן ומטופנ ור 	Assay	1 1203	70 % to 120 %
	 	i (By HPLC	ļ	of label claim
L	<u>!</u>	I (Dy IICLO	<u>_l</u>	OI IADEI CIAIIII

Laboratory Pragya Research Laboratories Pvt. Ltd., H-165, Second Floor, Sector-

63, Noida, Uttar Pradesh

Accreditation Standard ISO/IEC 17025: 2005

Certificate Number TC-7873 Page 5 of 6

Validity 26.09.2018 to 25.09.2020 Last Amended on --

SI.	Product / Material of Test	Specific Test Performed	Test Method Specification against which tests are performed	Range of Testing / Limits of Detection
		Dissolution(by HPLC)] 	50 % to 120%
<u>L</u>		<u>i</u>	<u> </u>	of label claim
4.	Cetirizine Tablets IP	Identification (By HPLC)	IP 2018 Page No.1561- 1562	Qualitative
	<u> </u> 	Assay	1	70% to 120 %
į		(By HPLC)		of label claim
		Dissolution		50 % to 120%
<u> </u>		(By UV)		of label claim
5.	Chlorpheniramine	Identification	IP 2018 Page 1598	Qualitative
į	Tablets	(By TLC)		<u> </u>
		Assay		70% to 120 %
į		(By UV)		of label claim
		Related Substances		Qualitative
į		(By TLC)		
6.	Ofloxacin Tablet	Identification	IP 2018 Page No.2769-	Qualitative
į	IP	(By HPLC)	2770	ii
	 	Assay		70% to 120 %
į		(By HPLC)		of label claim
 	 	Dissolution		50% to 120%
<u>i</u>	<u> </u>	(By UV)	<u> </u>	of label claim
7.	Paracetamol	Identification	IP 2018 Page No.2858	Qualitative
į	Tablet IP	(By IR)		<u> </u>
 	 	Assay		70 % to 120 %
į	į	(By UV)		of label claim
 		Dissolution	 	50% to 120%
<u>i</u>	<u> </u>	(By UV)		of label claim
8.	Ranitidine Tablet	Identification	IP 2018 Page No.3090	Qualitative
į		(By IR)		
 		Assay	 	70% to 120 %
<u> </u>	ļ 	(By HPLC)		of label claim
9.	Sildenafil Citrate	Identification	IP 2018 Page No.3191	Qualitative
į	Tablet IP	(By HPLC)		
	 	Assay	 	70% to 120 %
<u>i</u>	<u> </u>	(By HPLC)		of label claim

Accreditation Standard ISO/IEC 17025: 2005

Page 6 of 6 **Certificate Number** TC-7873

26.09.2018 to 25.09.2020 Validity Last Amended on --

SI.	Product / Material of Test	Specific Test Performed	Test Method Specification against which tests are performed	Range of Testing / Limits of Detection
	T	Dissolution (By UV)		50% to 120% of label claim
C.	INJECTION	(<u>by 0v)</u>	<u> </u>	
1.	Cyanocobalamin Injection	Identification (By UV)	IP 2018 Page No.1772- 1773	Qualitative
		Assay (By UV)		70% to 120% of label claim
į Į		Related Substances(BY HPLC)		Qualitative